Like pls t_老虎社区_美港股上老虎

MY21
2021-10-23

Like pls thanks

Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals

(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmac

Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":858194680,"tweetId":"858194680","gmtCreate":1634999983474,"gmtModify":1634999983734,"author":{"id":4088678245292670,"idStr":"4088678245292670","authorId":4088678245292670,"authorIdStr":"4088678245292670","name":"MY21","avatar":"https://static.tigerbbs.com/acfe94897c0513611a5d7beccb5c240d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls thanks&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Like pls thanks&nbsp;</p></body></html>","text":"Like pls thanks","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/858194680","repostId":2177414750,"repostType":4,"repost":{"id":"2177414750","kind":"news","pubTimestamp":1634955009,"share":"https://www.laohu8.com/m/news/2177414750?lang=&edition=full","pubTime":"2021-10-23 10:10","market":"us","language":"en","title":"Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2177414750","media":"Bloomberg","summary":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmac","content":"<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm <a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>., according to people familiar with the matter.</p>\n<p>The New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.</p>\n<p>Aurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.</p>\n<p>A spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.</p>\n<p>Formally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.</p>\n<p>The talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in <a href=\"https://laohu8.com/S/XLRN\">Acceleron Pharma Inc.</a> after Merck &amp; Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-23 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc","BMY":"施贵宝"},"source_url":"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177414750","content_text":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.\nAurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.\nA spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.\nFormally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.\nThe talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":793,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":13,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}